Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...

Please provide your email address to receive an email when new articles are posted on . Of 146 patients treated with dupilumab, 127 achieved disease control within 4 weeks. Complete remission was ...

Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...

Some dermatologists might be inclined to simply refer patients with blistering skin diseases, which are relatively rare, to an expert center, but they should not waive the effort to reach a diagnosis ...

DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023" report ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...